It's fascinating to speculate on what's going on,
Post# of 148154
Cancer Basket Trial
Develop protocol and launch CD20 Covid US
HIV-Prep BLA
HIV BLA filing
Cancer BBB BTD
Nash BTD
Amarex litigation
Brazil Severe/critical Covid trials
PI EUA approval
Canada TNBC approval expansion
LH protocol clinical trial launch
Identify and fill CEO position
Replace BOD position
Logic would suggest these items need to be triaged and responsibility assigned to each task.
I can think of many questions in each item, and it seems some of the items have fallen off the radar occasionally. Do we need to put some items on the "back burner?" It seems there is sufficient cash or stock on hand to cover our expenses for the near term.
Worst case scenario: we get no bail-out and must go it alone. We have a viable product, no credible person doubts the effectiveness of LL. We will need to seek our approval(s) where the best likelihood lies. Relentlessly, as if our future depends on it.
What we don't know:
Is there a suitor for BO or partnership? If so will, have the offer(s) been acceptable to shareholders?
How will the current/potential Amarex litigation be resolved?
Which of our current clinical trials will be resolved/approved?
Can we fund our aspirations?
Know where we are, where we want to go and how we are going to get there.